(BSc (Hons), 1983, PhD, 1989)
Dr. Graham has over 30 years of biopharmaceutical industry experience, having led development-stage programs across a range of therapeutic areas. He is currently SVP and Chief Development Officer at Avilar Therapeutics, working to develop a new class of extracellular protein degraders. Prior to Avilar, Dr. Graham held leadership positions at Sojournix, Concert Pharmaceuticals, and EPIX Pharmaceuticals. He holds a B.S. (honors) from the University of Otago, a Ph.D. in Analytical Chemistry from the University of Massachusetts, Amherst, and has authored more than 20 peer-reviewed publications.